Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.54 |
| ▸ | RARA | P10276 | 2/20 | 0.54 |
| ▸ | RARG | P13631 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 2/20 | 0.49 |
| ▸ | RXRA | P19793 | 5/20 | 0.48 |
| ▸ | RXRB | P28702 | 4/20 | 0.47 |
| ▸ | RXRG | P48443 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14011194 | 0.86 | MAOB (0.54) | RARBRARARARGALDH1A1EPHX2 | |
| SCHEMBL11888130 | 0.86 | METAP2 (0.51) | RARBRARARARGALDH1A1METAP2 | |
| SCHEMBL20847685 | 0.85 | RARB (0.68) | RARBRARARARGALDH1A1EPHX2 | |
| SCHEMBL6550099 | 0.85 | RARB (0.59) | RARBRARARARGEPHX2NR1H4 | |
| SCHEMBL667823 | 0.85 | ALDH1A1 (0.47) | RARBRARARARGALDH1A1EPHX2 | |
| SCHEMBL10211142 | 0.85 | DGAT1 (0.55) | RARBRARARARGEPHX2NR1H4 | |
| SCHEMBL1287171 | 0.83 | ALDH1A1 (0.54) | ALDH1A1METAP2RXRARXRBRAB9A | |
| SCHEMBL8252765 | 0.83 | GAA (0.47) | ALDH1A1HPGDTSHRMAP2K2MAP2K1 | |
| SCHEMBL4475121 | 0.82 | PIK3CA (0.41) | RARBRARARARGALDH1A1EPHX2 | |
| SCHEMBL9887754 | 0.82 | RARB (0.39) | RARBRARARARGALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601642-A4 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2007-04-11 | — | — | EP | claimed |
| EP-1601642-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078924-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2004-09-16 | — | — | WO | claimed |
| CN-118307541-A | Deuterated pyrazolopyrimidine derivative, preparation method thereof, pharmaceutical composition, conjugate and application | 天津济坤医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118304305-A | Application of deuterated pyrazolopyrimidine derivative in preparation of medicines for treating fibrotic diseases or immune inflammatory diseases | 天津济坤医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-113149981-B | Protein degradation targeting chimera for degrading androgen receptor | 苏州德亘生物医药有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-110272344-B | Camphorylimidazole type ionic liquid and preparation method and application thereof | 南京林业大学 | 2021-08-10 | — | — | CN | disclosed |
| CN-113149981-A | Protein degradation targeting chimera for degrading androgen receptor | 苏州德亘生物医药有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210094927-A1 | ISOTOPICALLY-STABILIZED TETRONIMIDE COMPOUNDS | MIDWESTERN UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| CN-108218848-B | Trifluoromethyl pyridine bisoxadiazole (ether) derivative and application thereof | 贵州大学 | 2020-12-18 | — | — | CN | disclosed |
| WO-2020231917-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-1601642-A4 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2007-04-11 | — | — | EP | disclosed |
| CN-1938305-A | 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof | SANOFI AVENTIS DEUTSCHLAND (US) | 2007-03-28 | — | — | CN | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1601642-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078924-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| CN-1052224-C | Peripheral Vasodilating agent containing N-acylated 4-amino piperidine derivatives as active ingredients | OTSUKA PHARMA CO LTD (JP) | 2000-05-10 | — | — | CN | disclosed |
| US-4046905-A | Anti-inflammatory, analgesic and antipyretic phenylacetic acids | MERCK & CO., INC. (US) | 1977-09-06 | — | — | US | disclosed |
| US-3947582-A | Phenylacetic acid compounds in treating abnormal platelet aggregation | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, NR5A1, NR5A2 | RARB 127/4885RARA 238/4885RARG 198/4885 |
| US-20210094927-A1 | ISOTOPICALLY-STABILIZED TETRONIMIDE COMPOUNDS | ASPH, BACE1, DNPEP | RARB 3103/4885RARA 3598/4885RARG 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.